uMotif, ActiGraph Announce eCOA/ePRO, Wearable Device Partnership

By Clinical Research News Staff 

February 6, 2023 | At the Summit for Clinical Ops Executives—SCOPE—event in Orlando, Fla., this week, uMotif and ActiGraph announced a partnership to make clinical trials more patient-centric and lower burden for participants. The partnership will leverage uMotif’s eCOA/ePRO platform, which streamlines patient engagement and data collection, and ActiGraph's leading expertise in clinical-grade wearable technology. The companies expect the result to be a seamless, patient-centered solution for clinical research. 

By working together, the companies plan to offer a more seamless, simple, and engaging patient experience for any research study. Sponsors are increasingly focused on making trials more patient-centric, particularly those adopting hybrid and decentralized designs and capturing a range of data from patients, sensors, and devices. New study designs can add complexity and burden for patients, sites, and CROs, which is compounded by the need to work with multiple systems. uMotif’s and ActiGraph’s unique expertise and design-led approach provides a highly engaging and patient-friendly solution to capture both subjective ePRO and objective device data through a single experience. 

Over the past ten years, uMotif has proven that a patient-centered approach is vital to delivering effective studies at pace and scale, with unrivaled volumes of quality data. uMotif studies have engaged thousands of participants who have captured millions of data points for published research.  The new partnership with ActiGraph allows sponsors to capture clinical-grade actigraphy data alongside validated, patient-friendly eCOA/ePRO instruments. 

In a press release, uMotif CEO Steve Rosenberg said, “We’re delighted to partner with ActiGraph.  Our eCOA/ePRO solutions combined with ActiGraph’s wearables and science-based algorithms and services are a big step forward in putting patients’ comfort and convenience at the center of research, so we can collect massive amounts of quality data while making their lives a bit easier.”   

In the same statement, ActiGraph CEO Jeremy Wyatt said, “Working with partners like uMotif makes the ActiGraph experience better for patients and clinicians. We are excited to collaborate on a combined solution that will help bring new treatments to market faster than ever.”